These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38898657)

  • 21. Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.
    Chandler D; Szekely C; Aggarwal S; Cyprien L; Bensink M
    Pain Ther; 2021 Dec; 10(2):1551-1566. PubMed ID: 34533779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database.
    Yu S; Zhang Y; Yao Y; Cao H
    J Headache Pain; 2020 May; 21(1):53. PubMed ID: 32404048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis.
    Roessler T; Zschocke J; Roehrig A; Friedrichs M; Friedel H; Katsarava Z
    J Headache Pain; 2020 Jul; 21(1):85. PubMed ID: 32631274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
    Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study.
    Watkins S; Toliver JC; Kim N; Whitmire S; Garvey WT
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1066-1079. PubMed ID: 35856489
    [No Abstract]   [Full Text] [Related]  

  • 30. Resource utilization impact of topiramate for migraine prevention in the managed-care setting.
    Wertz DA; Quimbo RM; Yaldo AZ; Rupnow MF
    Curr Med Res Opin; 2009 Feb; 25(2):499-503. PubMed ID: 19192995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
    Yi E; Dai D; Piao OW; Zheng JZ; Park Y
    J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
    J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data.
    Meyers JL; Davis KL; Lenz RA; Sakai F; Xue F
    Cephalalgia; 2019 Oct; 39(12):1518-1534. PubMed ID: 31154807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
    Varnado OJ; Hoyt M; Ye W; Nicholson R
    Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
    Buse DC; Krasenbaum LJ; Seminerio MJ; Packnett ER; Carr K; Ortega M; Driessen MT
    Pain Ther; 2024 Jun; 13(3):511-532. PubMed ID: 38472655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
    Lipton RB; Munjal S; Alam A; Buse DC; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
    Headache; 2018 Oct; 58(9):1408-1426. PubMed ID: 30341895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis.
    Hepp Z; Dodick DW; Varon SF; Chia J; Matthew N; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2017 Apr; 37(5):470-485. PubMed ID: 27837173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.